



Friday, December 7, 2007 - 11:24 AM CST

FDA approves Vidacare's new biopsy system for the market

San Antonio Business Journal

Vidacare Corp. has received Food and Drug Administration approval for the company's novel bone-marrow biopsy system for hematology/oncology.

The new technology is designed to increase control, improve core capture rates and reduce patient discomfort during bone-marrow biopsy procedures. San Antonio-based Vidacare will market the lithium-battery powered device under the OnControl Bone Marrow Biopsy System brand.

"The FDA's approval of the OnControl Biopsy System is a key milestone for Vidacare as well as patients requiring bone marrow biopsies," Vidacare President and CEO Philip Faris Jr. says.

"Bone marrow biopsies are the most frequently performed intraosseous diagnostic procedure in the U. S. and around the world."

Bone marrow biopsies are necessary for the diagnosis and management of lymphoma, leukemia, myeloma and other hematological disorders, company officials say.

Vidacare is a developer, manufacturer and marketer of advanced intraosseus (through-the-bone) access medical technology. Vidacare was founded in 2001 and the company licenses technologies developed at the University of Texas Health Science Center at San Antonio.

Web site: **www.vidacare.com**

All contents of this site © American City Business Journals Inc. All rights reserved.